Adaptimmune Therapeutics 대차 대조표 상태
재무 상태 기준 확인 4/6
Adaptimmune Therapeutics 의 총 주주 지분은 $80.0M 이고 총 부채는 $49.9M, 이는 부채 대 자기자본 비율을 62.3% 로 가져옵니다. 총자산과 총부채는 각각 $317.4M 및 $237.4M 입니다.
주요 정보
62.3%
부채 비율
US$49.87m
부채
| 이자 보상 비율 | n/a |
| 현금 | US$186.09m |
| 주식 | US$79.99m |
| 총 부채 | US$237.45m |
| 총 자산 | US$317.44m |
최근 재무 상태 업데이트
Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20
We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Recent updates
Investors Give Adaptimmune Therapeutics plc (NASDAQ:ADAP) Shares A 32% Hiding
Nov 15The Market Doesn't Like What It Sees From Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Revenues Yet As Shares Tumble 31%
Sep 26Adaptimmune's T-Cell Therapy Journey: A Small Market, Big Ambitions
Sep 12Adaptimmune: How The Story Is Shaping Up For The Latter Half Of 2024
Jul 03Adaptimmune: Huge Opportunity Amid Their Setback With Genentech
Apr 26Benign Growth For Adaptimmune Therapeutics plc (NASDAQ:ADAP) Underpins Stock's 29% Plummet
Apr 16Adaptimmune Therapeutics plc (NASDAQ:ADAP) Stock Catapults 107% Though Its Price And Business Still Lag The Industry
Feb 22Adaptimmune: Drug Approval Now Imminent?
Feb 02Adaptimmune Therapeutics plc's (NASDAQ:ADAP) Share Price Boosted 26% But Its Business Prospects Need A Lift Too
Dec 27News Flash: Analysts Just Made A Notable Upgrade To Their Adaptimmune Therapeutics plc (NASDAQ:ADAP) Forecasts
Nov 09New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Mar 08Adaptimmune Therapeutics (NASDAQ:ADAP) Is In A Good Position To Deliver On Growth Plans
Feb 20New Forecasts: Here's What Analysts Think The Future Holds For Adaptimmune Therapeutics plc (NASDAQ:ADAP)
Nov 09Adaptimmune Therapeutics: Depressed Despite Upcoming BLA
Sep 20We're Interested To See How Adaptimmune Therapeutics (NASDAQ:ADAP) Uses Its Cash Hoard To Grow
Sep 15Need To Know: The Consensus Just Cut Its Adaptimmune Therapeutics plc (NASDAQ:ADAP) Estimates For 2022
Aug 10Gene editing companies benefitting from Roche deal with CAR-T player Poseida Therapeutics
Aug 03Adaptimmune: Underappreciated Biotech With BLA Filing Q4 Of 2022
Jun 29Finally Returning To Adaptimmune Therapeutics Ahead Of Anticipated BLA
Jun 19Adaptimmune Therapeutics: A Little More Patience May Be Profitable
Mar 06Circling Back On Adaptimmune Therapeutics
Dec 15We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Dec 02Adaptimmune Therapeutics: Diverse Pipeline With Approval Looming
Sep 29We're Keeping An Eye On Adaptimmune Therapeutics' (NASDAQ:ADAP) Cash Burn Rate
Aug 14재무 상태 분석
단기부채: ADAP 의 단기 자산 ( $244.2M )이 단기 부채( $63.5M ).
장기 부채: ADAP 의 단기 자산( $244.2M )이 장기 부채( $174.0M ).
부채 대 자본 내역 및 분석
부채 수준: ADAP 총 부채보다 더 많은 현금을 보유하고 있습니다.
부채 감소: ADAP 의 부채 대 자기자본 비율은 지난 5년간 0% 에서 62.3% 로 증가했습니다.
대차 대조표
현금 런웨이 분석
과거에 평균적으로 적자를 기록했던 기업의 경우, 최소 1년 이상의 현금 유동성을 보유하고 있는지 평가합니다.
안정적인 현금 활주로: ADAP 현재 무료 현금 흐름을 기준으로 3년 이상 충분한 현금 활주로를 보유하고 있습니다.
예측 현금 활주로: ADAP 의 여유 현금 흐름이 역사적 비율에 따라 계속 증가하거나 감소하는 경우 충분한 현금 활주로가 있는지 판단하기에는 데이터가 부족합니다.